Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | KDM5C | P41229 | 2/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257927 | 0.82 | PRMT1 (0.63) | ITGB3ITGA2BTSHRPLA2G2ALMNA | |
| SCHEMBL493520 | 0.82 | PRMT1 (0.63) | ITGB3ITGA2BTSHRPLA2G2ALMNA | |
| SCHEMBL4811356 | 0.82 | ECE1 (0.60) | ECE1ITGB3ITGA2BFAAHCNR1 | |
| SCHEMBL9717431 | 0.81 | ECE1 (0.65) | ECE1ITGB3ITGA2BFAAHCNR1 | |
| SCHEMBL9717468 | 0.81 | ECE1 (0.81) | ECE1ITGB3ITGA2BFAAHCNR1 | |
| SCHEMBL134099 | 0.81 | ALDH1A1 (0.39) | ECE1KDM4ETSHRLMNA | |
| SCHEMBL27858651 | 0.79 | ECE1 (0.70) | ECE1ITGB3ITGA2BFAAHCNR1 | |
| SCHEMBL8531287 | 0.79 | ECE1 (0.62) | ECE1ITGB3ITGA2BFAAHCNR1 | |
| SCHEMBL30905813 | 0.79 | PRMT1 (0.59) | ITGB3ITGA2BFAAHCNR1CNR2 | |
| SCHEMBL7765966 | 0.78 | ALDH1A1 (0.46) | ECE1ITGB3ITGA2BKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2023-12-12 | — | — | US | claimed |
| CN-111480080-B | Method for improving therapeutic cell quality by real-time glutathione measurement | 塞尔吐温株式会社 | 2023-09-19 | — | — | CN | claimed |
| CN-111492248-B | Method for measuring therapeutic cell mass by real-time glutathione assay | 塞尔吐温株式会社 | 2023-09-12 | — | — | CN | claimed |
| US-11498979-B2 | Methods for preparing a purified maytansinoid conjugate in a solution | IMMUNOGEN, INC. (US) | 2022-11-15 | — | — | US | claimed |
| US-11499978-B2 | Method for measuring quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2022-11-15 | — | — | US | claimed |
| US-20210163625-A1 | CONJUGATION METHODS | IMMUNOGEN SWITZERLAND GMBH (CH) | 2021-06-03 | — | — | US | claimed |
| US-20210003582-A1 | Method for Improving Quality of Therapeutic Cell Through Real-Time Glutathione Measurement | CELL2IN, INC. (KR) | 2021-01-07 | — | — | US | claimed |
| US-20200363422-A1 | Method for Measuring Quality of Therapeutic Cell Through Real-Time Glutathione Measurement | CELL2IN, INC. (KR) | 2020-11-19 | — | — | US | claimed |
| US-10815309-B2 | Methods for preparing antibody-drug conjugates | IMMUNOGEN, INC. (US) | 2020-10-27 | — | — | US | claimed |
| EP-3719501-A1 | METHOD FOR MEASURING QUALITY OF THERAPEUTIC CELL THROUGH REAL-TIME GLUTATHIONE MEASUREMENT | Cell2in, Inc. (KR) | 2020-10-07 | — | — | EP | claimed |
| EP-2903450-A1 | USE OF AN ION EXCHANGE MEMBRANE TO REMOVE IMPURITIES FROM CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140309406-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | IMMUNOGEN, INC. | 2014-10-16 | — | — | US | claimed |
| US-8795673-B2 | Preparation of maytansinoid antibody conjugates by a one-step process | IMMUNOGEN, INC. (US) | 2014-08-05 | — | — | US | claimed |
| US-20140179906-A1 | CONJUGATION METHODS | IMMUNOGEN, INC. (US) | 2014-06-26 | — | — | US | claimed |
| WO-2014055893-A1 | USE OF AN ION EXCHANGE MEMBRANE TO REMOVE IMPURITIES FROM CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | IMMUNOGEN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| WO-2014055877-A1 | USE OF A PVDF MEMBRANE TO PURIFY CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | IMMUNOGEN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2691155-A2 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | Immunogen, Inc. (US) | 2014-02-05 | — | — | EP | claimed |
| US-8624003-B2 | Methods for preparation of antibody-maytansinoid conjugates | IMMUNOGEN, INC. (US) | 2014-01-07 | — | — | US | claimed |
| US-20120253021-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | US | claimed |
| WO-2012135517-A2 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179906-A1 | CONJUGATION METHODS | FCGR2A, FCGR3B, CD47 | ECE1 2382/4885ITGB3 481/4885ITGA2B 297/4885 |
| US-11498979-B2 | Methods for preparing a purified maytansinoid conjugate in a solution | CD69, PAICS, CD47 | ECE1 1017/4885ITGB3 1339/4885ITGA2B 1645/4885 |
| US-10815309-B2 | Methods for preparing antibody-drug conjugates | CD47, FCGR2A, FCGR3B | ECE1 2862/4885ITGB3 283/4885ITGA2B 200/4885 |
| US-20210163625-A1 | CONJUGATION METHODS | FCGR2A, FCGR3B, CD47 | ECE1 2326/4885ITGB3 510/4885ITGA2B 325/4885 |
| US-11499978-B2 | Method for measuring quality of therapeutic cell through real-time glutathione measurement | GGT1, GSR, GPX1 | ECE1 2495/4885ITGB3 4083/4885ITGA2B 4387/4885 |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | GSR, GPX1, GGT1 | ECE1 2806/4885ITGB3 3962/4885ITGA2B 4007/4885 |
| US-20140309406-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | CD47, CD22, CLSPN | ECE1 1074/4885ITGB3 1343/4885ITGA2B 1072/4885 |
| US-20120253021-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | CD47, CD22, CLSPN | ECE1 1074/4885ITGB3 1343/4885ITGA2B 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.